• All
  • Important
  • Financial Update
  • Fund Raise
  • Board Meeting
  • Dividend/Bonus
  • JV/Acquisition
  • Investor Meet
  • Insider Trade
  • Pledging
  • Others
    ALPHA TRIBE

    Sun Pharma Advanced Research Company Limited — Board Meeting, 09-02-2026: Outcome of Board Meeting

    09-02-2026 | 01:30 pm

    SPARC's board approved Q3/9M consolidated results: a ₹80.42 Cr loss for Q3 and ₹208.14 Cr loss for 9M, which includes a ₹12.36 Cr exceptional cost. A key win: US FDA granted a Priority Review Voucher for Sezaby®! Promoter support ensures its 'Going Concern' status.

    No comments yet. Be the first to comment!

    All announcements from Sun Pharma Advanced Research Company Limited